The 48th annual meeting of the European Association for the Study of the Liver.
The regimen is being studied as a potential interferon alfa-, ribavirin – and ritonavir-free treatment option to avoid the tolerability and drug-drug interaction profiles of these medicines. On April 24 These triple DAA data will be highlighted in the state ILC Press Conference. An analysis of all available safety data on 1,100 individuals who received daclatasvir plus interferon alfa and ribavirin in Phase 2 studies. These data support the ongoing Phase 3 development system for daclatasvir and additional research of daclatasvir as a component of DAA-structured HCV treatment regimens. A characterization of ALT flares seen in hepatitis B treatment with the investigational interferon Lambda vs. Alfa interferon, reflecting differing profiles for both compounds.Jan. The first place team’s college receives a $2,500 scholarship. Second place: Purdue University University of Pharmacy, with team members Hannah Han Le, Dong Helen Shao, Limin Zhang, Madeline Merkel and faculty advisor Amy Heck. The second place group’s college receives a $1,500 scholarship. Third Place: University of Minnesota University of Pharmacy, with team members Rebecca Pulk, Scott Baird, Mary Walter, Ryan faculty and Langem advisor Randall Seifert.